Literature DB >> 16386194

Heart and liver fatty acid binding proteins and the metabolic syndrome.

Bert Binas1.   

Abstract

Cytosolic fatty acid binding proteins (FABPs) are widely expressed fatty acid chaperones. The adipocyte-expressed FABPs are permissive factors for the fat-induced metabolic syndrome, but a similar relevance of the FABPs of heart, muscle, and liver remains unclear. In this article, the known biochemical and physiologic roles of these FABPs are discussed in this context. It is concluded that the observations on adipocyte-expressed FABPs cannot be automatically extended to other tissues. More work is needed to clarify whether the individual or combined inhibition of FABPs is a desirable strategy to treat the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16386194     DOI: 10.1007/s11906-005-0033-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  49 in total

Review 1.  The fatty acid transport function of fatty acid-binding proteins.

Authors:  J Storch; A E Thumser
Journal:  Biochim Biophys Acta       Date:  2000-06-26

2.  Impaired long-chain fatty acid utilization by cardiac myocytes isolated from mice lacking the heart-type fatty acid binding protein gene.

Authors:  F G Schaap; B Binas; H Danneberg; G J van der Vusse; J F Glatz
Journal:  Circ Res       Date:  1999-08-20       Impact factor: 17.367

Review 3.  Cytosolic fatty acid binding proteins catalyze two distinct steps in intracellular transport of their ligands.

Authors:  Richard A Weisiger
Journal:  Mol Cell Biochem       Date:  2002-10       Impact factor: 3.396

Review 4.  Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years.

Authors:  P J Randle
Journal:  Diabetes Metab Rev       Date:  1998-12

5.  Calcium-binding protein S100A7 and epidermal-type fatty acid-binding protein are associated in the cytosol of human keratinocytes.

Authors:  G Hagens; I Masouyé; E Augsburger; R Hotz; J H Saurat; G Siegenthaler
Journal:  Biochem J       Date:  1999-04-15       Impact factor: 3.857

6.  Improved glucose and lipid metabolism in genetically obese mice lacking aP2.

Authors:  K T Uysal; L Scheja; S M Wiesbrock; S Bonner-Weir; G S Hotamisligil
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

7.  Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein.

Authors:  G S Hotamisligil; R S Johnson; R J Distel; R Ellis; V E Papaioannou; B M Spiegelman
Journal:  Science       Date:  1996-11-22       Impact factor: 47.728

8.  Role of the fatty acid binding protein mal1 in obesity and insulin resistance.

Authors:  Kazuhisa Maeda; K Teoman Uysal; Liza Makowski; Cem Z Görgün; Genichi Atsumi; Rex A Parker; Jens Brüning; Ann Vogel Hertzel; David A Bernlohr; Gökhan S Hotamisligil
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

9.  Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene.

Authors:  Elizabeth P Newberry; Yan Xie; Susan Kennedy; Xianlin Han; Kimberly K Buhman; Jianyang Luo; Richard W Gross; Nicholas O Davidson
Journal:  J Biol Chem       Date:  2003-10-08       Impact factor: 5.157

10.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.

Authors:  S S Lee; T Pineau; J Drago; E J Lee; J W Owens; D L Kroetz; P M Fernandez-Salguero; H Westphal; F J Gonzalez
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

View more
  1 in total

1.  Increased glucose oxidation in H-FABP null soleus muscle is associated with defective triacylglycerol accumulation and mobilization, but not with the defect of exogenous fatty acid oxidation.

Authors:  Sean Adhikari; Erdal Erol; Bert Binas
Journal:  Mol Cell Biochem       Date:  2006-08-15       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.